Flerie Expands Investor Access to Private Life Science Firms with Strategic Evergreen Model

Flerie, under CEO Ted Fjällman, is advancing its focus on the life sciences sector by providing investors exclusive access to private companies often overlooked by public markets. With a portfolio consisting of 25 companies, 17 of which are Swedish, Flerie has 77% of its capital invested in private firms across therapeutic areas including heart failure, cancer, and rare diseases. This diversification covers early-stage biotech projects and companies with commercial growth potential.

Operating on an innovative evergreen investment model, Flerie offers ongoing support to portfolio companies that continue to generate value, thus facilitating long-term growth while carefully managing investment risks. The firm’s approach balances exposure and risk, aiming to prioritize projects with the highest potential for success. Moreover, Flerie leverages a broad international network of syndicate investors to secure funding, even in challenging market conditions.

Flerie's commitment to improving market accessibility was highlighted by its investment role in NorthX Biologics, which received substantial growth capital from Signet Healthcare Partners in 2025, fueling its biological drug development. Since listing on Nasdaq Stockholm in June 2024, Flerie has gained recognition amid rising investor demand for stable yet innovative life science opportunities.

CEO Ted Fjällman emphasized the transformative possibilities presented by their portfolio companies, underlining the firm’s drive to broaden investor access to pioneering health technologies while maintaining rigorous risk management. This strategic positioning reflects an evolving life science investment landscape where accessibility and active portfolio management are key to sustainable success.